Agri Investment Fund

Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptake of nutrients from the soil.

Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptake of nutrients from the soil.

Animab is a biotechnology company specializing in proprietary technology that supports livestock health. Animab combines cutting-edge research, animal science, and biotechnology to create products that improve animal health, reduce costs, and are more sustainable. Animab provides a safe and long-term solution for protecting piglets' intestinal health during the critical post-weaning stage. The antibodies in Animab are designed to mimic secretory IgA, a type of natural antibody that is passed through colostrum and milk to protect nursing animals.

ViroVet is a pioneering company dedicated to the development of disruptive and innovative technologies for the control of viral diseases in livestock, with antiviral drugs for respiratory disease complexes and innovative vaccines for viral infections in swine leading the pipeline. The livestock industry is a 100+ billion-euro industry. Viral diseases cost producers billions every year in losses and threaten the world supply of animal protein. The strategy of ViroVet is to provide novel solutions to be used alone or in combination with vaccines and biosecurity measures in order to provide livestock producers, national governments and international organizations with a multi-faceted arsenal of virus control weapons against endemic and epizootic viral diseases. It is clear that with the growing world population there is an increased demand for more protein-rich diets. With the increasing density of the livestock industry, the intensifying global trade and climate changes, there is an ever increased risk for the global spread of viral diseases, severely damaging livestock industry. ViroVet has already enlisted the support of a number of key opinion leaders (KOLs) in livestock medicine confirming the extensive market for antiviral drugs and novel vaccines addressing the challenges of spreading viral diseases. KOLs feel that ViroVet’s products have the potential to reduce the use of antibiotics and revolutionize the livestock industry worldwide.

Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combine the high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications. It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.

Aphea.Bio will develop next generation ‘biopesticides’ based on natural microorganisms. These products will provide an alternative for chemical pesticides, which are currently under serious pressure. In addition, the company will develop novel ‘biostimulants’, i.e. microorganisms that stimulate crop growth, for example through promoting the uptake of nutrients from the soil.

Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases. The strategic acquisition of Okapi further enhances Aratana's leadership position in pet therapeutics by bringing with it a unique combination of individuals, strong relationships with academic institutions, novel technologies and products, and favorable geographic location. Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises.

Fugeia NV is develops ingredients and nutrition technologies. The company offers arabinoxylan-oligosaccharides (AXOS) ingredient that provides the health benefits of wholegrain wheat as part of the human diet, particularly in the prevention of lifestyle diseases, such as diabetes, obesity, cardiovascular diseases, and cancer; Prebiotic bread technology that allows to increase the level of arabinoxylan-oligosaccharides in bread; and AXOS-enriched beer technology that allows to increase the level of arabinoxylan-oligosaccharides. It develops products and technologies targeted for a range of market segments, including dairy and non-dairy beverages, ready-to-eat cereals, cookies and biscuits, and bread and pastry, as well as dietary supplements and therapeutics.